10/5-6/2010: Development of Type 2 Diabetes Mellitus Drugs: State-of-the-Art Cardiovascular Safety Assessments Oct. 5-6, 2010

10/5-6/2010: Development of Type 2 Diabetes Mellitus Drugs: State-of-the-Art Cardiovascular Safety Assessments Oct. 5-6, 2010

Call for abstracts deadline: September 8, 2010

Featured Conference Topics:

  • Optimal Clinical Trial Designs
  • Diabetes Mellitus Regulatory Guidances
  • Post-marketing Assessments
  • Preclinical Testing to Evaluate CV Risk and Mechanistic Considerations
  • Biomarkers, Pharmacogenomics, and Collaborative Efforts

Featured FDA Speakers:

  • Dr. Robert J. Temple, Deputy Center Director for Clinical Science, CDER
  • Dr. Mary Parks, Director, Division of Metabolism and Endocrinology Products, Office of Drug Evaluation II, Office of New Drugs, CDER
  • Dr. Norman Stockbridge, Director, Division of Cardiovascular and Renal Products, Office of Drug Evaluation I, Office of New Drugs, CDER
  • Dr. Ilan Irony, Clinical Team Leader, Division of Metabolism and Endocrinology Products, Office of New Drugs, CDER
  • Dr. Hylton V. Joffe, Lead Medical Officer, Diabetes Drug Group I, Division of Metabolism and Endocrinology Products, Office of New Drugs, CDER
  • Dr. J. Todd Sahlroot, Deputy Director and Team Leader, Office of Translational Sciences, Office of Biostatistics, CDER

Brochure

More information about this event…